{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T11:06:50Z","timestamp":1762427210526,"version":"build-2065373602"},"reference-count":60,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2025,9,10]],"date-time":"2025-09-10T00:00:00Z","timestamp":1757462400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,9,10]],"date-time":"2025-09-10T00:00:00Z","timestamp":1757462400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Med Oncol"],"DOI":"10.1007\/s12032-025-03003-w","type":"journal-article","created":{"date-parts":[[2025,9,10]],"date-time":"2025-09-10T09:18:55Z","timestamp":1757495935000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Deciphering the molecular landscape of acute myeloid leukemia initiation and relapse: a systems biology approach"],"prefix":"10.1007","volume":"42","author":[{"given":"Atefeh","family":"Bahmei","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hanieh","family":"Fadakar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8158-6004","authenticated-orcid":false,"given":"Gholamhossein","family":"Tamaddon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,9,10]]},"reference":[{"issue":"5","key":"3003_CR1","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1002\/ajh.27625","volume":"100","author":"S Shimony","year":"2025","unstructured":"Shimony S, Stahl M, Stone RM. Acute myeloid leukemia: 2025 update on diagnosis, risk-stratification, and management. Am J Hematol. 2025;100(5):860\u201391.","journal-title":"Am J Hematol"},{"issue":"3","key":"3003_CR2","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1007\/s11864-017-0456-2","volume":"18","author":"P Bose","year":"2017","unstructured":"Bose P, Vachhani P, Cortes JE. Treatment of relapsed\/refractory acute myeloid leukemia. Curr Treat Options Oncol. 2017;18(3):17.","journal-title":"Curr Treat Options Oncol"},{"issue":"7","key":"3003_CR3","doi-asserted-by":"publisher","first-page":"811","DOI":"10.3727\/096504020X15965357399750","volume":"28","author":"A Patel","year":"2021","unstructured":"Patel A, Agha M, Raptis A, Hou JZ, Farah R, Redner RL, et al. Outcomes of patients with acute myeloid leukemia who relapse after 5 years of complete remission. Oncol Res. 2021;28(7):811\u20134.","journal-title":"Oncol Res"},{"issue":"10","key":"3003_CR4","doi-asserted-by":"publisher","first-page":"1320","DOI":"10.1182\/blood-2016-08-734798","volume":"129","author":"MS Shafat","year":"2017","unstructured":"Shafat MS, Oellerich T, Mohr S, Robinson SD, Edwards DR, Marlein CR, et al. Leukemic blasts program bone marrow adipocytes to generate a protumoral microenvironment. Blood. 2017;129(10):1320\u201332.","journal-title":"Blood"},{"issue":"6","key":"3003_CR5","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1016\/j.annonc.2020.02.018","volume":"31","author":"M Heuser","year":"2020","unstructured":"Heuser M, Ofran Y, Boissel N, Mauri SB, Craddock C, Janssen J, et al. Acute myeloid leukaemia in adult patients: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2020;31(6):697\u2013712.","journal-title":"Ann Oncol"},{"issue":"3","key":"3003_CR6","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1016\/j.bbamcr.2015.08.015","volume":"1863","author":"F Chiarini","year":"2016","unstructured":"Chiarini F, Lonetti A, Evangelisti C, Buontempo F, Orsini E, Evangelisti C, et al. Advances in understanding the acute lymphoblastic leukemia bone marrow microenvironment: from biology to therapeutic targeting. Biochimica et Biophysica Acta (BBA)-Molecular Cell Research. 2016;1863(3):449\u201363.","journal-title":"Biochimica et Biophysica Acta (BBA)-Molecular Cell Research"},{"issue":"1\u20132","key":"3003_CR7","first-page":"7","volume":"4","author":"R Schofield","year":"1978","unstructured":"Schofield R. The relationship between the spleen colony-forming cell and the haemopoietic stem cell. Blood Cells. 1978;4(1\u20132):7\u201325.","journal-title":"Blood Cells"},{"issue":"1","key":"3003_CR8","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1111\/bjh.16044","volume":"187","author":"J Ma","year":"2019","unstructured":"Ma J, Liu B, Yu D, Zuo Y, Cai R, Yang J, et al. Sirt3 deacetylase activity confers chemoresistance in AML via regulation of mitochondrial oxidative phosphorylation. Br J Haematol. 2019;187(1):49\u201364.","journal-title":"Br J Haematol"},{"key":"3003_CR9","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.775128","volume":"12","author":"T Marchand","year":"2021","unstructured":"Marchand T, Pinho S. Leukemic stem cells: from leukemic niche biology to treatment opportunities. Front Immunol. 2021;12: 775128.","journal-title":"Front Immunol"},{"key":"3003_CR10","doi-asserted-by":"publisher","first-page":"444","DOI":"10.3389\/fonc.2018.00444","volume":"8","author":"L Behrmann","year":"2018","unstructured":"Behrmann L, Wellbrock J, Fiedler W. Acute myeloid leukemia and the bone marrow niche-take a closer look. Front Oncol. 2018;8:444.","journal-title":"Front Oncol"},{"issue":"3","key":"3003_CR11","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1016\/j.stem.2014.06.020","volume":"15","author":"M Hanoun","year":"2014","unstructured":"Hanoun M, Zhang D, Mizoguchi T, Pinho S, Pierce H, Kunisaki Y, et al. Acute myelogenous leukemia-induced sympathetic neuropathy promotes malignancy in an altered hematopoietic stem cell niche. Cell Stem Cell. 2014;15(3):365\u201375.","journal-title":"Cell Stem Cell"},{"issue":"10","key":"3003_CR12","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1080\/10245332.2018.1486064","volume":"23","author":"A Wang","year":"2018","unstructured":"Wang A, Zhong H. Roles of the bone marrow niche in hematopoiesis, leukemogenesis, and chemotherapy resistance in acute myeloid leukemia. Hematology. 2018;23(10):729\u201339.","journal-title":"Hematology"},{"issue":"6","key":"3003_CR13","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1007\/s00432-025-06244-4","volume":"151","author":"MJ Saadh","year":"2025","unstructured":"Saadh MJ, Torabi Fard N, Hussein A, Mirzazadeh A, Siavashi M, SeyedMoharami F, et al. Mesenchymal stem cells in the bone marrow microenvironment: a double-edged sword for AML. J Cancer Res Clin Oncol. 2025;151(6):193.","journal-title":"J Cancer Res Clin Oncol"},{"issue":"21","key":"3003_CR14","doi-asserted-by":"publisher","first-page":"5319","DOI":"10.3390\/cancers13215319","volume":"13","author":"M Ciciarello","year":"2021","unstructured":"Ciciarello M, Corradi G, Forte D, Cavo M, Curti A. Emerging bone marrow microenvironment-driven mechanisms of drug resistance in acute myeloid leukemia: tangle or chance? Cancers. 2021;13(21):5319.","journal-title":"Cancers"},{"issue":"3","key":"3003_CR15","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1016\/j.stem.2015.02.019","volume":"16","author":"Y Kfoury","year":"2015","unstructured":"Kfoury Y, Scadden DT. Mesenchymal cell contributions to the stem cell niche. Cell Stem Cell. 2015;16(3):239\u201353.","journal-title":"Cell Stem Cell"},{"issue":"9","key":"3003_CR16","doi-asserted-by":"publisher","first-page":"2279","DOI":"10.1002\/ijc.32063","volume":"144","author":"S Yehudai-Resheff","year":"2019","unstructured":"Yehudai-Resheff S, Attias-Turgeman S, Sabbah R, Gabay T, Musallam R, Fridman-Dror A, et al. Abnormal morphological and functional nature of bone marrow stromal cells provides preferential support for survival of acute myeloid leukemia cells. Int J Cancer. 2019;144(9):2279\u201389.","journal-title":"Int J Cancer"},{"issue":"1","key":"3003_CR17","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.arcmed.2020.08.006","volume":"52","author":"DE Rodr\u00edguez-Fuentes","year":"2021","unstructured":"Rodr\u00edguez-Fuentes DE, Fern\u00e1ndez-Garza LE, Samia-Meza JA, Barrera-Barrera SA, Caplan AI, Barrera-Salda\u00f1a HA. Mesenchymal stem cells current clinical applications: a systematic review. Arch Med Res. 2021;52(1):93\u2013101.","journal-title":"Arch Med Res"},{"issue":"4","key":"3003_CR18","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1111\/bjh.17940","volume":"196","author":"HMM Ahmed","year":"2022","unstructured":"Ahmed HMM, Nimmagadda SC, Al-Matary YS, Fiori M, May T, Frank D, et al. Dexamethasone-mediated inhibition of Notch signalling blocks the interaction of leukaemia and mesenchymal stromal cells. Br J Haematol. 2022;196(4):995\u20131006.","journal-title":"Br J Haematol"},{"issue":"6","key":"3003_CR19","doi-asserted-by":"publisher","first-page":"1659","DOI":"10.1002\/2211-5463.13165","volume":"11","author":"Zp Pan","year":"2021","unstructured":"Pan Zp, Wang B, Hou Dy, You Rl, Wang Xt, Xie Wh, et al. METTL3 mediates bone marrow mesenchymal stem cell adipogenesis to promote chemoresistance in acute myeloid leukaemia. FEBS Open Bio. 2021;11(6):1659\u201372.","journal-title":"FEBS Open Bio"},{"key":"3003_CR20","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2024.e25081","author":"M Vukoti\u0107","year":"2024","unstructured":"Vukoti\u0107 M, Kapor S, Simon F, Cokic V, Santibanez JF. Mesenchymal stromal cells in myeloid malignancies: immunotherapeutic opportunities. Heliyon. 2024. https:\/\/doi.org\/10.1016\/j.heliyon.2024.e25081.","journal-title":"Heliyon"},{"issue":"7","key":"3003_CR21","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1038\/s41592-019-0456-1","volume":"16","author":"W Mao","year":"2019","unstructured":"Mao W, Zaslavsky E, Hartmann BM, Sealfon SC, Chikina M. Pathway-level information extractor (PLIER) for gene expression data. Nat Methods. 2019;16(7):607\u201310.","journal-title":"Nat Methods"},{"key":"3003_CR22","unstructured":"Society LL. Acute myeloid leukemia 2025 [Available from: https:\/\/www.lls.org\/leukemia\/acute-myeloid-leukemia."},{"issue":"16","key":"3003_CR23","doi-asserted-by":"publisher","first-page":"4431","DOI":"10.1182\/blood-2011-02-334136","volume":"118","author":"K Kojima","year":"2011","unstructured":"Kojima K, McQueen T, Chen Y, Jacamo R, Konopleva M, Shinojima N, et al. P53 activation of mesenchymal stromal cells partially abrogates microenvironment-mediated resistance to FLT3 inhibition in AML through HIF-1\u03b1-mediated down-regulation of CXCL12. Blood. 2011;118(16):4431\u20139.","journal-title":"Blood"},{"key":"3003_CR24","volume":"28","author":"EE Aung","year":"2022","unstructured":"Aung EE, Yamsri S, Teawtrakul N, Kamsaen P, Fucharoen S. FLT3 gene mutations in acute myeloid leukemia patients in Northeast Thailand. Med Sci Monit Basic Res. 2022;28: e937446.","journal-title":"Med Sci Monit Basic Res"},{"key":"3003_CR25","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2021.764698","volume":"9","author":"DB Pimenta","year":"2021","unstructured":"Pimenta DB, Varela VA, Datoguia TS, Caraciolo VB, Lopes GH, Pereira WO. The bone marrow microenvironment mechanisms in acute myeloid leukemia. Front Cell Dev Biol. 2021;9: 764698.","journal-title":"Front Cell Dev Biol"},{"issue":"W1","key":"3003_CR26","doi-asserted-by":"publisher","first-page":"W98","DOI":"10.1093\/nar\/gkx247","volume":"45","author":"Z Tang","year":"2017","unstructured":"Tang Z, Li C, Kang B, Gao G, Li C, Zhang Z. GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses. Nucleic Acids Res. 2017;45(W1):W98\u2013102.","journal-title":"Nucleic Acids Res"},{"issue":"6","key":"3003_CR27","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1038\/s41423-023-01034-9","volume":"20","author":"J Zhou","year":"2023","unstructured":"Zhou J, Shi Y. Mesenchymal stem\/stromal cells (MSCs): origin, immune regulation, and clinical applications. Cell Mol Immunol. 2023;20(6):555\u20137.","journal-title":"Cell Mol Immunol"},{"issue":"3","key":"3003_CR28","doi-asserted-by":"publisher","first-page":"165","DOI":"10.5045\/br.2019.54.3.165","volume":"54","author":"E Fathi","year":"2019","unstructured":"Fathi E, Sanaat Z, Farahzadi R. Mesenchymal stem cells in acute myeloid leukemia: a focus on mechanisms involved and therapeutic concepts. Blood research. 2019;54(3):165.","journal-title":"Blood research"},{"key":"3003_CR29","doi-asserted-by":"publisher","DOI":"10.1016\/j.addr.2021.114069","volume":"181","author":"C Lee-Thedieck","year":"2022","unstructured":"Lee-Thedieck C, Schertl P, Klein G. The extracellular matrix of hematopoietic stem cell niches. Adv Drug Deliv Rev. 2022;181: 114069.","journal-title":"Adv Drug Deliv Rev"},{"issue":"5","key":"3003_CR30","doi-asserted-by":"publisher","first-page":"2527","DOI":"10.3390\/ijms25052527","volume":"25","author":"C-H Wu","year":"2024","unstructured":"Wu C-H, Weng T-F, Li J-P, Wu K-H. Biology and therapeutic properties of mesenchymal stem cells in leukemia. Int J Mol Sci. 2024;25(5):2527.","journal-title":"Int J Mol Sci"},{"key":"3003_CR31","doi-asserted-by":"publisher","first-page":"1000996","DOI":"10.3389\/fimmu.2022.1000996","volume":"13","author":"M Luciano","year":"2022","unstructured":"Luciano M, Krenn PW, Horejs-Hoeck J. The cytokine network in acute myeloid leukemia. Front Immunol. 2022;13:1000996.","journal-title":"Front Immunol"},{"issue":"3","key":"3003_CR32","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1038\/s41375-018-0373-9","volume":"33","author":"MW Lee","year":"2019","unstructured":"Lee MW, Ryu S, Kim DS, Lee JW, Sung KW, Koo HH, et al. Mesenchymal stem cells in suppression or progression of hematologic malignancy: current status and challenges. Leukemia. 2019;33(3):597\u2013611.","journal-title":"Leukemia"},{"issue":"6","key":"3003_CR33","doi-asserted-by":"publisher","first-page":"77","DOI":"10.3892\/or.2024.8736","volume":"51","author":"R Li","year":"2024","unstructured":"Li R, Wang D, Yang H, Pu L, Li X, Yang F, et al. Important role and underlying mechanism of non-SMC condensin I complex subunit G in tumours. Oncol Rep. 2024;51(6):77.","journal-title":"Oncol Rep"},{"issue":"1","key":"3003_CR34","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/sj.onc.1208017","volume":"24","author":"R W\u00e4sch","year":"2005","unstructured":"W\u00e4sch R, Engelbert D. Anaphase-promoting complex-dependent proteolysis of cell cycle regulators and genomic instability of cancer cells. Oncogene. 2005;24(1):1\u201310.","journal-title":"Oncogene"},{"key":"3003_CR35","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrc.2025.152040","author":"L Yu","year":"2025","unstructured":"Yu L, Han W, Zhang J, Liu G, Li H, Xu Y, et al. Repurposing HIV protease inhibitors as senotherapeutic agents in cervical cancer: dual targeting of CDK1\/6-cell cycle arrest and p53\/p21\/p16 signaling axis. Biochem Biophys Res Commun. 2025. https:\/\/doi.org\/10.1016\/j.bbrc.2025.152040.","journal-title":"Biochem Biophys Res Commun"},{"key":"3003_CR36","doi-asserted-by":"publisher","DOI":"10.1016\/j.cellsig.2025.111919","author":"H Zhang","year":"2025","unstructured":"Zhang H, He X, Yang L, Yang F, Chen R, Wen Z, et al. Trim45: an emerging E3 ubiquitin ligases in cancer. Cell Signal. 2025. https:\/\/doi.org\/10.1016\/j.cellsig.2025.111919.","journal-title":"Cell Signal"},{"issue":"6","key":"3003_CR37","doi-asserted-by":"publisher","first-page":"77","DOI":"10.3892\/or.2024.8736","volume":"51","author":"R Li","year":"2024","unstructured":"Li R, Wang D, Yang H, Pu L, Li X, Yang F, et al. Important role and underlying mechanism of non-SMC condensin I complex subunit G in tumours (review). Oncol Rep. 2024;51(6):77.","journal-title":"Oncol Rep"},{"key":"3003_CR38","doi-asserted-by":"publisher","first-page":"387","DOI":"10.3389\/fphar.2020.00387","volume":"11","author":"C Xiao","year":"2020","unstructured":"Xiao C, Gong J, Jie Y, Cao J, Chen Z, Li R, et al. NCAPG is a promising therapeutic target across different tumor types. Front Pharmacol. 2020;11:387.","journal-title":"Front Pharmacol"},{"key":"3003_CR39","doi-asserted-by":"publisher","first-page":"2657","DOI":"10.2147\/CCID.S390770","volume":"15","author":"D Xie","year":"2022","unstructured":"Xie D, Chen X, Wu H, Ning D, Cao X, Wan C. Prediction of diagnostic gene biomarkers associated with immune infiltration for basal cell carcinoma. Clin Cosmet Investig Dermatol. 2022;15:2657\u201373.","journal-title":"Clin Cosmet Investig Dermatol"},{"issue":"5","key":"3003_CR40","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1179\/1607845413Y.0000000125","volume":"19","author":"Y Cohen","year":"2014","unstructured":"Cohen Y, Gutwein O, Garach-Jehoshua O, Bar-Haim A, Kornberg A. The proliferation arrest of primary tumor cells out-of-niche is associated with widespread downregulation of mitotic and transcriptional genes. Hematology. 2014;19(5):286\u201392.","journal-title":"Hematology"},{"issue":"8","key":"3003_CR41","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.4161\/cc.24313","volume":"12","author":"A Hedblom","year":"2013","unstructured":"Hedblom A, Laursen KB, Miftakhova R, Sarwar M, Anagnostaki L, Bredberg A, et al. CDK1 interacts with RAR\u03b3 and plays an important role in treatment response of acute myeloid leukemia. Cell Cycle. 2013;12(8):1251\u201366.","journal-title":"Cell Cycle"},{"key":"3003_CR42","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.1016\/j.biopha.2017.05.056","volume":"91","author":"C Xu","year":"2017","unstructured":"Xu C, Sun L, Jiang C, Zhou H, Gu L, Liu Y, et al. SPP1, analyzed by bioinformatics methods, promotes the metastasis in colorectal cancer by activating EMT pathway. Biomed Pharmacother. 2017;91:1167\u201377.","journal-title":"Biomed Pharmacother"},{"issue":"1","key":"3003_CR43","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1186\/s12935-022-02749-x","volume":"22","author":"X Yi","year":"2022","unstructured":"Yi X, Luo L, Zhu Y, Deng H, Liao H, Shen Y, et al. SPP1 facilitates cell migration and invasion by targeting COL11A1 in lung adenocarcinoma. Cancer Cell Int. 2022;22(1):324.","journal-title":"Cancer Cell Int"},{"key":"3003_CR44","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2021.646390","volume":"9","author":"H Tang","year":"2021","unstructured":"Tang H, Chen J, Han X, Feng Y, Wang F. Upregulation of SPP1 is a marker for poor lung cancer prognosis and contributes to cancer progression and cisplatin resistance. Front Cell Dev Biol. 2021;9: 646390.","journal-title":"Front Cell Dev Biol"},{"issue":"36","key":"3003_CR45","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000035038","volume":"102","author":"F Xian","year":"2023","unstructured":"Xian F, Zhao C, Huang C, Bie J, Xu G. The potential role of CDC20 in tumorigenesis, cancer progression and therapy: a narrative review. Medicine (Baltimore). 2023;102(36): e35038.","journal-title":"Medicine (Baltimore)"},{"issue":"4","key":"3003_CR46","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1111\/bjh.18541","volume":"200","author":"C Tian","year":"2023","unstructured":"Tian C, Chen Z, Wang L, Si J, Kang J, Li Y, et al. Over expression of ubiquitin-conjugating enzyme E2O in bone marrow mesenchymal stromal cells partially attenuates acute myeloid leukaemia progression. Br J Haematol. 2023;200(4):476\u201388.","journal-title":"Br J Haematol"},{"issue":"5","key":"3003_CR47","first-page":"508","volume":"2","author":"D Schnerch","year":"2012","unstructured":"Schnerch D, Yalcintepe J, Schmidts A, Becker H, Follo M, W\u00e4sch R. Cell cycle control in acute myeloid leukemia. Am J Cancer Res. 2012;2(5):508\u201328.","journal-title":"Am J Cancer Res"},{"issue":"6","key":"3003_CR48","doi-asserted-by":"publisher","first-page":"1296","DOI":"10.1038\/leu.2016.350","volume":"31","author":"A Quint\u00e1s-Cardama","year":"2017","unstructured":"Quint\u00e1s-Cardama A, Hu C, Qutub A, Qiu YH, Zhang X, Post SM, et al. p53 pathway dysfunction is highly prevalent in acute myeloid leukemia independent of TP53 mutational status. Leukemia. 2017;31(6):1296\u2013305.","journal-title":"Leukemia"},{"issue":"1","key":"3003_CR49","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1007\/s11033-023-09185-8","volume":"51","author":"A Asghari-Ghomi","year":"2024","unstructured":"Asghari-Ghomi A, Fallahian F, Garavand J, Mohammadi MH. WT1 and TP53 as valuable diagnostic biomarkers for relapse after hematopoietic stem cell transplantation in acute myeloid leukemia. Mol Biol Rep. 2024;51(1):244.","journal-title":"Mol Biol Rep"},{"issue":"6","key":"3003_CR50","doi-asserted-by":"publisher","first-page":"1535","DOI":"10.1038\/s41375-019-0377-0","volume":"33","author":"SC Nabinger","year":"2019","unstructured":"Nabinger SC, Chen S, Gao R, Yao C, Kobayashi M, Vemula S, et al. Mutant p53 enhances leukemia-initiating cell self-renewal to promote leukemia development. Leukemia. 2019;33(6):1535\u20139.","journal-title":"Leukemia"},{"issue":"6","key":"3003_CR51","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1093\/labmed\/lmae048","volume":"55","author":"L Zhang","year":"2024","unstructured":"Zhang L, Abro B, Campbell A, Ding Y. TP53 mutations in myeloid neoplasms: implications for accurate laboratory detection, diagnosis, and treatment. Lab Med. 2024;55(6):686\u201399.","journal-title":"Lab Med"},{"key":"3003_CR52","doi-asserted-by":"publisher","DOI":"10.2174\/0109298673319496240911060138","author":"N Garg","year":"2024","unstructured":"Garg N, Farhat J, Dhankhar S, Chauhan S, Bala R, Madaan R, et al. Vincristine in cancer therapy: mechanisms, efficacy, and future perspectives. Curr Med Chem. 2024. https:\/\/doi.org\/10.2174\/0109298673319496240911060138.","journal-title":"Curr Med Chem"},{"issue":"6","key":"3003_CR53","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1016\/j.bjan.2019.08.004","volume":"69","author":"J Yazdani","year":"2019","unstructured":"Yazdani J, Khorshidi Khiavi R, Ghavimi MA, Mortazavi A, Jabbari Hagh E, Ahmadpour F. Calcitonin as an analgesic agent: review of mechanisms of action and clinical applications. Rev Bras Anestesiol. 2019;69(6):594\u2013604.","journal-title":"Rev Bras Anestesiol"},{"key":"3003_CR54","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2023.114420","volume":"161","author":"Z Qian","year":"2023","unstructured":"Qian Z, Chen L, Liu J, Jiang Y, Zhang Y. The emerging role of PPAR-alpha in breast cancer. Biomed Pharmacother. 2023;161: 114420.","journal-title":"Biomed Pharmacother"},{"issue":"13","key":"3003_CR55","doi-asserted-by":"publisher","first-page":"15577","DOI":"10.18632\/oncotarget.6402","volume":"7","author":"K Chandran","year":"2015","unstructured":"Chandran K, Goswami S, Sharma-Walia N. Implications of a peroxisome proliferator-activated receptor alpha (PPAR\u03b1) ligand clofibrate in breast cancer. Oncotarget. 2015;7(13):15577.","journal-title":"Oncotarget"},{"issue":"Suppl 2","key":"3003_CR56","doi-asserted-by":"publisher","first-page":"1060","DOI":"10.1007\/s12070-017-1120-7","volume":"71","author":"MV Kirtane","year":"2019","unstructured":"Kirtane MV, Bhandari A, Narang P, Santani R. Cinnarizine: a contemporary review. Indian J Otolaryngol Head Neck Surg. 2019;71(Suppl 2):1060\u20138.","journal-title":"Indian J Otolaryngol Head Neck Surg"},{"issue":"2","key":"3003_CR57","doi-asserted-by":"publisher","first-page":"139","DOI":"10.4103\/pajr.pajr_22_21","volume":"11","author":"TM Attia","year":"2021","unstructured":"Attia TM, Rawat V. Role of cinnarizine as an adjuvant treatment in cases of postviral hyposmia. Pan Arab J Rhinol. 2021;11(2):139\u201344.","journal-title":"Pan Arab J Rhinol"},{"issue":"2","key":"3003_CR58","first-page":"835","volume":"35","author":"LC Schmeel","year":"2015","unstructured":"Schmeel LC, Schmeel FC, Kim Y, Blaum-Feder S, Endo T, Schmidt-Wolf IG. In vitro efficacy of cinnarizine against lymphoma and multiple myeloma. Anticancer Res. 2015;35(2):835\u201341.","journal-title":"Anticancer Res"},{"issue":"13_Supplement","key":"3003_CR59","doi-asserted-by":"publisher","first-page":"2475","DOI":"10.1158\/1538-7445.AM2017-2475","volume":"77","author":"L Robillard","year":"2017","unstructured":"Robillard L, Nguyen M, Harding TC, Simmons AD. In vitro and in vivo assessment of the mechanism of action of the PARP inhibitor rucaparib. Cancer Res. 2017;77(13_Supplement):2475.","journal-title":"Cancer Res"},{"key":"3003_CR60","doi-asserted-by":"publisher","DOI":"10.2147\/CMAR.S353411","author":"MS Wu","year":"2022","unstructured":"Wu MS, Goldberg H. Role of rucaparib in the treatment of prostate cancer: clinical perspectives and considerations. Cancer Manag Res. 2022. https:\/\/doi.org\/10.2147\/CMAR.S353411.","journal-title":"Cancer Manag Res"}],"container-title":["Medical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-025-03003-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12032-025-03003-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-025-03003-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T11:02:50Z","timestamp":1762426970000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12032-025-03003-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,10]]},"references-count":60,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2025,11]]}},"alternative-id":["3003"],"URL":"https:\/\/doi.org\/10.1007\/s12032-025-03003-w","relation":{},"ISSN":["1559-131X"],"issn-type":[{"type":"electronic","value":"1559-131X"}],"subject":[],"published":{"date-parts":[[2025,9,10]]},"assertion":[{"value":"28 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"468"}}